Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesNew early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development
Haemophilia, 11/04/09
Kurnik K et al. – The results indicate that minimizing danger signals during the first 20 EDs with FVIII may reduce the risk of inhibitor formation. These results should be confirmed in a larger prospective clinical study.
Karin Kurnik, 11/05/09
| Today, the most serious and costly complication of the treatment of hemophilia A that remains to be overcome is the development of inhibitory antibodies (FVIII inhibitors) to FVIII replacement therapy. In this paper we present a new early prophylaxis regimen that is shown to reduce the inhibitor risk in previously untreated children with severe hemophilia A by avoiding immunological danger signals within the first FVIII exposure days. Although our results should be interpreted as hypothesis generating and would need to be confirmed in a larger prospective clinical study we think that they are very important for hemophilia care givers in order to develop safer hemophilia treatment regimens that can reduce the risk of inhibitor development in previously untreated patients. Another benefit of the new prophylaxis regimen is that the proposed once weekly administration is simpler for parents, requiring only one visit to the hemophilia centre each week, so that compliance with and control of the therapy is easier to achieve. There would be also a pharmacoeconomic benefit in that the proposed lower doses and less frequent administration can allow considerable cost savings compared with standard prophylactic regimens. |
Today in Coagulation/Bleeding Dz...keeping you current
Receive free subspecialty "5-minute updates" via email
Approach to Thrombocytopenia in Older Adults
Geriatrics & Aging, 11/10/09
The influence of low-dose aspirin and hydroxyurea on platelet-leukocyte interactions in patients with essential thrombocythemia
Blood Coagulation & Fibrinolysis, 11/03/09
Medical treatments for idiopathic thrombocytopenic purpura during pregnancy
Cochrane Reviews, 10/27/09
Sponsor
Article Search
Sponsor
Sponsor